HTS Hit Triage: How to Turn Primary Actives Into Real Hits

HTS hit triage is the structured process of sorting the actives from a high-throughput screen into compounds worth chasing and compounds that are noise. You do it with a cascade of filters: confirm the activity, rule out assay interference, prove target engagement with a different technology, then rank what survives by chemistry quality and series potential. Done well, it channels a finite budget into compounds with a real chance of becoming leads. Done badly, it hands your medicinal chemists a list of artifacts.

This guide walks through the cascade step by step, with the failure modes that cost teams the most time, and a note on where computational work fits.

TL;DR

• Triage is a cascade, not a single filter: confirm, remove artifacts, validate with an orthogonal method, then prioritize by series.
• Non-biased HTS typically yields hit rates of only 0.01% to 0.1%, so most primary actives need a hard look.
• Treat PAINS alerts as a prioritization guide, never a rigid exclusion rule, and always back them with experimental proof of target engagement.
• Favor scaffold diversity and consistent SAR over large piles of near-identical analogs.
• Computational triage works best when it is built around your assay and validated against your own ground-truth data.

Table of Contents

• What hit triage actually decides
• Step 1: Confirm the actives
• Step 2: Remove interference and artifacts
• Step 3: Prove target engagement with an orthogonal method
• Step 4: Cluster, rank and choose series
• Where computational triage helps most
• Triage for phenotypic screens is different
• A worked example of a triage funnel
• Common mistakes in HTS hit triage
• Our perspective
• How Innova Biotech can support your triage
• FAQ
• Sources

What hit triage actually decides

A primary screen gives you a list of compounds that crossed an activity threshold. That is not a list of hits in the sense your project needs. The goal of triage, as one widely cited review of HTS data analysis frames it, is to prioritize a subset of the many detected actives for further investigation and optimization.

Three decisions sit inside that goal:

1. Is the activity real and reproducible? Does the compound show the same effect on retest, from fresh material, with a sensible dose-response?
2. Is the activity caused by the target? Or by aggregation, reactivity, fluorescence, metal chelation or some other interference with the readout?
3. Is the compound worth optimizing? Does it have a tractable scaffold, acceptable properties and room to improve potency and selectivity?

The first two decisions are about biology and assay behavior. The third is about chemistry and economics. Teams that skip the second tend to discover the problem in the most expensive way: after months of hit-to-lead work on a compound that never engaged the target.

Step 1: Confirm the actives

Before anything clever, repeat the experiment. A useful confirmation stage includes:

• Retest in duplicate or triplicate at the original concentration, ideally from a freshly prepared stock.
• Dose-response curves (typically 8 to 10 points) to get an initial potency estimate and check curve shape. Steep, bell-shaped or incomplete curves are early warnings.
• Compound identity and purity checks by LC-MS. A surprising number of apparent hits turn out to be degradation products or impurities.
• Cherry-picking from the original library plate versus resupplying powder. Comparing the two tells you whether activity travels with the structure.

Record everything in a single table keyed by compound ID. Every later decision depends on being able to see assay results, QC data and structure side by side.

Step 2: Remove interference and artifacts

This is where most false positives die. A hit, in the working sense, is a molecule with reproducible, measurable activity against a target in a primary assay. But primary hits frequently include false positives caused by interference, as described in the brief guide to experimental hit selection strategies: autofluorescence, compound aggregation, signal quenching and non-specific binding.

A 2024 Nature Reviews Chemistry paper on assay interference names the main culprits for biochemical and cell-based assays: colloidal aggregation, chemical reactivity, chelation, and light signal attenuation or emission.

Match the counter-screen to the mechanism

A practical rule: design the counter-screens before the primary screen finishes, using what you know about your readout. If the primary assay is fluorescence-based, plan for a fluorescence-interference read from day one.

Use computational filters, with judgment

Substructure filters are fast and essential at scale. They remove reactive and unattractive groups before you spend a cent on follow-up. But they are blunt instruments.

The Phantom PAINS study points out that PAINS alerts became a common part of triage even though they were originally derived from a limited set of screening data. Many compounds that carry an alert are not universally promiscuous and can be genuine actives in a specific assay. Our reading of the literature: use PAINS alerts to rank risk, then let an experiment decide.

The same logic applies in the other direction. The review on data-driven HTS approaches stresses that filters must be combined with experimental ground truth. Over-filter and you discard novel chemotypes. Under-filter and the team chases false leads that fail later, when failure is more expensive.

Step 3: Prove target engagement with an orthogonal method

Passing counter-screens tells you what a compound is not doing. Orthogonal validation tells you what it is doing. The idea is simple: confirm the same biological effect using a different readout technology, so any artifact tied to the first detection method cannot repeat.

If your primary assay used fluorescence, validate with luminescence or a label-free biophysical technique. The experimental hit selection guide recommends exactly this approach, with methods such as SPR and ITC for confirming that a compound is not just interfering with the detection hardware.

A sensible order for biophysics

Biophysical methods differ in cost, throughput and the amount of protein they consume. A tiered approach keeps spending proportional to confidence:

1. Thermal shift assay (TSA): cheap, fast, low protein use. Good as a first filter for non-specific compounds.
2. SPR: gives binding kinetics and stoichiometry, and exposes non-specific or super-stoichiometric binding.
3. NMR or ITC: more labor- and material-intensive, reserved for the compounds you most want to believe.

A 2024 SLAS Discovery analysis ran biophysical assays on several hundred hits from 15 different HTS campaigns to confirm target engagement. A caution drawn from practitioners using TSA this way: it has a false negative rate of around 13% for reversible inhibitors, so a negative TSA result is a reason to look closer for a high-priority compound, not an automatic rejection. Its value is as a low-cost filter that keeps non-specific compounds away from SPR and NMR time.

Step 4: Cluster, rank and choose series

Once you have a pool of validated actives, the question shifts from "is it real?" to "which ones deserve chemistry?"

Prioritize scaffolds, not single compounds

The data-driven triage literature recommends organizing hits into scaffold trees early. The reasoning: a large set of analogs that all share an artifact-inducing property can inflate your false-positive rate, while a series with consistent activity across multiple members is far more believable. Lone compounds with no neighbors showing structure-activity relationships (SAR) are the classic frequent hitters you want to deprioritize.

A useful scoring sheet for each series includes:

• Number of confirmed members and potency range
• Presence of a visible SAR trend (small changes produce predictable potency shifts)
• Ligand efficiency and lipophilic efficiency
• Physicochemical properties and rule-of-five position
• Synthetic tractability and availability of analogs
• Novelty against known chemotypes and your intellectual property position
• Selectivity data from any counter-targets already run

Keep a diversity quota

It is tempting to promote the ten most potent compounds, which are often analogs of each other. Keep at least a few weaker but structurally distinct series alive. Early potency is the property most likely to change during optimization, while a poor scaffold rarely improves.

Where computational triage helps most

Computational methods earn their place at three points in the cascade.

Before the screen. Virtual screening can enrich the library you test. The ACS review on virtual screening strategies for novel chemotypes notes that virtual screening can raise hit rates significantly compared with non-biased HTS. A structure-based virtual screening analysis shows why the numbers matter: for a scheme with 10% recall and a 1% false positive rate, positive predictive value climbs from 0.01% to 10% as the library hit rate rises from 0.001% to 1%. In other words, the same method looks very different depending on the base rate it faces.

During triage. Docking poses, interaction fingerprints and ligand-based similarity can test whether a confirmed active plausibly binds where you think it does. Disagreement between a compound's pose and the SAR in its series is a flag worth investigating. We cover validation practices in more detail in our guide to validating virtual screening results and on reducing false positives in virtual screening.

After triage. Early in silico ADMET and selectivity predictions help you pick between series that look equal on potency. See our notes on in silico ADMET and predictive in silico selectivity.

Triage for phenotypic screens is different

Target-based triage leans on biophysical proof of binding. Phenotypic triage has no single target to engage, so it leans on biological knowledge instead. The Vincent and colleagues review of phenotypic hit triage is often cited for the idea that successful triage depends on known mechanisms, disease biology and safety knowledge. Because we cannot verify more about that paper here, we leave the details to the original.

In practice, phenotypic teams add counter-screens for cytotoxicity, run the active set against related pathways, and begin target deconvolution in parallel. For a timeline-driven approach, see our biology-first hit triage workflow for phenotypic teams, and for an overview of assay formats, our guide to preclinical screening assay types.

A worked example of a triage funnel

The numbers below are illustrative, not data from a real project. They show the typical shape of attrition, which is what you should plan resources around.

The point of the funnel is that each stage is cheaper per compound than the one after it. Order your filters accordingly: cheap and broad first, expensive and specific last.

Common mistakes in HTS hit triage

• Applying PAINS as a hard cutoff. You will lose real chemotypes and keep artifacts that carry no alert.
• Validating with the same technology. A second fluorescence assay is a replicate, not an orthogonal test.
• Promoting by potency alone. Potent compounds are often aggregators or analogs of one scaffold.
• Triaging in silos. Biology, chemistry and computational teams reviewing the same table together catch problems that each team misses alone.
• Skipping documentation. Without recorded reasons for each rejection, the team will relitigate decisions or revisit dead ends.
• Running counter-screens after the fact. Design them as the primary assay is built.

Our perspective

We work on the computational side of this problem, and our view is shaped by one pattern: the best triage is designed around the specific assay and target, not copied from a generic checklist. A filter set that works for a kinase biochemical screen can mislead on a protein-protein interaction or a cell-based readout.

That is why our approach to virtual screening and hit-to-lead work is tailored to each project, and why we stay in close contact with the experimental team. Computation should narrow the field and explain the data, and the bench should have the final word on target engagement. We would rather give a client a short, defensible list with the reasoning attached than a long ranked list that no one trusts.

We also think data discipline matters as much as method. Confidential structures, assay results and series rankings deserve strict handling from the first conversation, and clear updates at each stage keep everyone aligned on what the numbers can and cannot support.

— Hooman

How Innova Biotech can support your triage

If your team has a primary screen in hand, or is planning one, we can help you build the computational side of the cascade: structure-based and ligand-based screening to enrich or re-rank actives, and hit-to-lead support that carries the best series forward. Our virtual screening and hit-to-lead service is scoped to each project, with scientists working alongside your team from the first consultation through delivery. You can also read how we think about cutting hit-to-lead time with data-driven funnels, or get in touch through our main site.

FAQ

What does HTS hit triage mean?

It is the process of prioritizing the active compounds from a high-throughput screen so that only the most credible ones move on. The process confirms activity, removes assay artifacts, validates target engagement and ranks the survivors by chemical quality and series potential.

How is a hit different from a lead?

A hit is a compound with reproducible activity against a target in an assay. A lead is a validated hit series that has been improved enough in potency, selectivity and properties to justify full optimization. Triage decides which hits are worth carrying into hit-to-lead work.

Should I remove every PAINS-flagged compound?

No. Research on PAINS alert utility shows that many flagged compounds are not universally promiscuous. Treat an alert as a reason to scrutinize a compound harder and to run an orthogonal assay, not as automatic grounds for removal.

What is an orthogonal assay?

It is an assay that measures the same biological effect with a different detection technology. For example, a hit from a fluorescence readout can be tested by luminescence or by a label-free method such as SPR. Because the readouts differ, an artifact of the first one is unlikely to repeat.

Can computational methods replace experimental triage?

No. Models and filters speed up processing of large datasets and help rank risk, but reviews of the field stress that they must be combined with experimental data. Computation narrows the list and explains it. Binding and activity still need to be confirmed at the bench.

Sources

• Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns
• Creating a more strategic small molecule biophysical hit characterization workflow
• Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening
• Tackling assay interference associated with small molecules
• Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS
• Virtual Screening Strategies for Identifying Novel Chemotypes
• The Science and Art of Structure-Based Virtual Screening
• Hit Triage and Validation in Phenotypic Screening

Recommended

• 5–7 Week Biology First Hit Triage Workflow for Phenotypic Teams
• Cut Hit-to-Lead to One Month: Data-Driven Funnels for Drug Teams
• Cut Attrition: Lead Prioritization for R&D With Five Criteria and FEP